Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07628881 | A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults | PHASE1 | NOT YET_RECRUITING | 12 | — | — | Jun 18, 2026 | Sep 27, 2026 | Jun 5, 2026 | - | — |
| Arm | Type | Description |
|---|---|---|
| Sonrotoclax Tablet for Oral Suspension | EXPERIMENTAL | Participants will receive each of the following treatments as a single dose on 3 separate occasions with an 8-day washout in between: 1. oral dose of sonrotoclax tablet for oral suspension administered in the fed state with a high-fat meal. 2. oral dose of sonrotoclax tablet for oral suspension administered after fasting 3. oral dose of sonrotoclax tablet administered in the fed state with a high-fat meal. |
| Name | Type | Description |
|---|---|---|
| Sonrotoclax Tablet for Oral Suspension | DRUG | Administered orally |
| Sonrotoclax Tablet | DRUG | Administered orally |
Inclusion Criteria: * Participants must sign the informed consent form (ICF) and be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. * Participants who are overtly healthy as determined by no clinica...